 Superiority ProMACE-CytaBOM ProMACE-MOPP treatment advanced diffuse aggressive lymphoma results prospective trial erratum Clin Oncol Apr ninety-three patients stage II III IV follicular large-cell large-cell diffuse mixed immunoblastic small noncleaved-cell non-Burkitt lymphoma cyclophosphamide IV IV IV day mechlorethamine IV vincristine cap mg total dose IV day prednisone daily days procarbazine daily days IV day leucovorin hours doses hours methotrexate cycles days ProMACE-MOPP treatment ProMACE-MOPP cytarabine IV IV vincristine cap mg total dose IV IV day hours doses hours methotrexate daily days cycles days ProMACE-CytaBOM Co-trimoxazole double-strength tablets period treatment ProMACE-CytaBOM regimen risk Pneumocystis carinii pneumonia first patients combination Median follow-up years patients ProMACE-MOPP complete remission CR complete responders patients treatment-related causes patients ProMACE-CytaBOM CR complete responders patients complete response rate survival patients ProMACE-CytaBOM mortality ProMACE-CytaBOM treatment overall patients treatment-related mortality patients prophylactic co-trimoxazole ProMACE-CytaBOM combination chemotherapy co-trimoxazole prophylaxis safe effective treatment patients aggressive histology malignant lymphoma superior ProMACE-MOPP